CCKBR and medullary thyroid gland carcinoma: Radiolabeled MG analogs with the modified receptor-specific C-terminal sequence Trp-(N-Me)Nle-Asp-1Nal-NH2 are promising new candidates for diagnostic and therapeutic use in patients with advanced MTC and other CCK2R-expressing malignancies.